Your session is about to expire
← Back to Search
Pembrolizumab/Vibostolimab + Chemoradiotherapy for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer treatment that uses two drugs, pembrolizumab and vibostolimab, in combination with standard chemotherapy and radiation therapy. The new treatment is being compared to standard chemotherapy and radiation therapy followed by a different drug, durvalumab. The primary hypotheses are that the new treatment will improve progression-free survival and overall survival in patients with non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My scans show no signs of cancer spread beyond my lungs.I have received drugs to boost my white blood cells within the last 28 days.I have received an organ or tissue transplant from another person.I have not had major surgery in the last 4 weeks or have fully recovered from it if I did.You are expected to live for at least 6 months.I cannot stop taking aspirin or NSAIDs for a few days around my treatment.My lung cancer is at Stage III and cannot be removed by surgery.I am currently being treated for an infection.I have been treated for an autoimmune disease in the last 2 years.I have not received a live vaccine in the last 30 days.I have had radiation therapy to my chest area before.I am fully active or restricted in physically strenuous activity but can do light work.My cancer is small cell lung cancer or has small cell elements.I have another cancer that has gotten worse or needed treatment in the last 5 years.My cancer can be measured and has a targetable lesion.My lung cancer diagnosis is confirmed by lab tests.I will need cancer treatment other than the study's while participating.My lung cancer is at stage IIIA, IIIB, or IIIC.I haven't had any treatment for my Stage III lung cancer.I cannot or will not take folic acid, vitamin B12, and dexamethasone.I have provided a sample of my tumor for testing.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I have a history of Hepatitis B or an active Hepatitis C infection.You have been diagnosed with HIV.I have or had lung inflammation that needed steroids.
- Group 1: pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy
- Group 2: chemotherapy+radiotherapy+durvalumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do pembrolizumab/vibostolimab have any long-term side effects?
"Pembrolizumab/vibostolimab's safety is estimated to be a 3. This comes from it being a Phase 3 trial, which has some data supporting efficacy and multiple rounds of safety data."
Are we able to sign up for this testing program at the present moment?
"That is correct, the online clinicaltrials.gov database has that this study, which was first posted on May 3rd 2022, presently recruiting participants. The research team hopes to enroll 784 patients from 7 different locations."
Share this study with friends
Copy Link
Messenger